Replies to post #88201 on Anavex Life Sciences Corp (AVXL)

[mapman1010]

thank you Dok. i believe it is a big deal as well.

[jimmy667]

Rett's trial is the pivotal test of A2-73. It will be quick and if it is decisive it will figuratively sink the "short thesis fleet." The fact that AVXL will do this quick decisive trial first should relieve any suspicions or doubts about Anavex Management's confidence in A2-73. If AVXL wins this one they will be quickly joined by very powerful allies, and eventual successes in the bigger indications will most likely be assured. If they fail it will not be the end but it could be a more difficult and lonely endeavor. I like that they are taking the chance for the quick decisive victory.
Anavex Life Sciences "Think differently and have NO FEAR!"

[plexrec]

Doktor....I agree with your optimism but I question your statement"It is a fall-back if the (non orphan main population of) Alzheimer's path fizzles out"---I see no chance of the "Alzheimer's path" fizzling out ! All systems are "GO" with Caulfield Hospital in Melbourne reviewing-signing up-ph 2/3 trial participants as I write. Just say'in !

[Bourbon_on_my_cornflakes]

"Approval on phase 2 is not super common, but this is an orphan disease and a double blind trial. That is the right combination for early approval."

Spot on! They are looking to show efficacy by doing it this way. With no treatments for rett's, superior 273 safety profile, and orphan status, a good trial result should lead to accelerated approval after p2....which means potential approval this year!